<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00516204</url>
  </required_header>
  <id_info>
    <org_study_id>NIS-CAT-CRE-2007/3</org_study_id>
    <secondary_id>NIS-CAT-DUM-2007/3</secondary_id>
    <nct_id>NCT00516204</nct_id>
  </id_info>
  <brief_title>Diabetic Under 70 (Diabetics Below 70)</brief_title>
  <official_title>Diabetic Under 70 (Diabetics Below 70)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      A screening project of diabetics with a very high cardiovascular risk (e.g. diabetes plus
      coronary heart disease) who already receive cholesterol-lowering therapy. Lipid profile and
      rate of patients who are treated to target (which is &lt;70mg/dl for such patients with very
      high risk) are screened. The doctors therapy decisions after the screening will be documented
      and 8-10 weeks later the lipid profile of each patient will be evaluated again. Our aim is to
      evaluate dosing habits, to evaluate how many patients are treated to their LDL-C target and
      to underline the importance of treating patients to their cholesterol targets.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cholesterol levels</measure>
    <time_frame>After 4 weeks</time_frame>
    <description>Cholesterol levels from high risk patients after 4 weeks of cholesterol-lowering drug therapy under target values</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">685</enrollment>
  <condition>Diabetes</condition>
  <condition>Hyperlipidemia</condition>
  <condition>Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>Patients at very high risk</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients at high risk</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients at medium risk</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients at low risk</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Male and female secondary prevention patients with: coronary disease with event: acute
        coronary syndrome, status post MI, PTCA, CABG, angiographically verified), PAVK (min. IIb
        or S.p. revascularization), stroke/TIA, carotis-plaque (asymptomatic min. 70% or S.p.
        revascularization), Diabetes Mellitus (type I, II)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diabetics with hyperlipidemia and atherosclerosis (coronary heart disease, carotid
             stenosis, PAVK, etc.) who already receive cholesterol-lowering therapy

        Exclusion Criteria:

          -  Diabetics w/o CVD; diabetics who do not receive cholesterol-lowering therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Roden, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Chairs of the Austrian Diabetes Society</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 14, 2007</study_first_submitted>
  <study_first_submitted_qc>August 14, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2007</study_first_posted>
  <last_update_submitted>October 29, 2014</last_update_submitted>
  <last_update_submitted_qc>October 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 30, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hyperlipidemia</keyword>
  <keyword>Diabetics</keyword>
  <keyword>NIS</keyword>
  <keyword>Diabetics with hyperlipidemia and atherosclerosis (coronary heart disease, carotid stenosis, PAVK, etc.)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

